Assessment of the patients’ glycaemic control while hospitalised showed no difference between groups in the requirement for additional insulin or additional orally administered agents in patients with T2DM or an increase in insulin dose in patients with T1DM or T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.